Table 6.

Items regarding CS5: Patient with non-functioning GEP-NET, non-susceptible to surgery or to loco-regional treatment, with Ki-67 > 10 %, ECOG ≤2, AND POSITIVE OCTREOSCAN®: Is SSA treatment initiated? [36, 59]

	Previous rounda	Median (p25-p75)	Median range	Participants in median range n (%)	Result
41. The use of SSA in monotherapy in these patients is reasonable in patients with Ki-67 <20 %.	50.8 %: 7–9	7 (7–8)	7–9	48 (84.2)	C - A
42. The use of SSA in monotherapy in these patients is reasonable in case of low tumor load (hepatic ≤25 % and no extra-hepatic disease).	63.1 %: 7–9	8 (7–8)	7–9	50 (87.7)	C - A
43. The use of SSA in monotherapy in these patients is reasonable in case of NETs of gastrointestinal origin.	52.3 %: 7–9	7 (7–8)	7–9	49 (86)	C - A
44. In case of important comorbidities, SSAs are an option in these patients.		8 (7–9)	7–9	56 (86.2)	C - A
45. In these patients with Ki-67 from 10 to 20 % and/or high tumor load (extra-hepatic and/or hepatic >25 %) and/or NET of pancreatic origin, treatment is usually initiated with chemotherapy.	66.2 %: 7–9	7 (7–8)	7–9	48 (84.2)	C - A
46. In these patients with Ki-67 from 10 to 20 % and/or high tumor load (extra-hepatic and/or hepatic >25 %) and/or NET of pancreatic origin, treatment is usually initiated with molecular targeted drugs (with the possibility of combination with SSA).		7 (6–8)	7–9	45 (69.2)	C - A
47. If discrepancy exists between the degree of cellular proliferation and the octreoscan® results, it is recommended to perform 18FDG-PET-TAC to help making a therapeutic decision.	53.8 %: 7–9	7 (7–8)	7–9	46 (80.7)	C - A
48. If discrepancy exists between the degree of cellular proliferation and the octreoscan® results, a re-biopsy of the growing lesions will be considered.	64.4 %: 7–9	7 (7–8)	7–9	53 (93)	C - A

CS Clinical situation, SSAs Somatostatin analogs, GEP Gastroenteropancreatic, NET Neuroendocrine tumor, C consensus, NC non-consensus, A Agreement

^aOnly applies to statements with 2 rounds; participant % in median range: median range